The latest regulation on biosimilars in China lays out more clearly the circumstances under which developers of such products would have to apply and get approval for specific indications, a situation that might apply to some of the world’s biggest-selling biologics available in the country as these come under increasing biosimilar pressure.
A rising number of such original products are seeing such emerging competition in China, where some large manufacturers are now leaping into the fray as revenues from their mature products come under pressure. Major domestic firms including Qilu Pharmaceutical Co., Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?